Brad Kahl, MD
Enriched profileProfessor of Medicine, Division of Oncology; Director, Lymphoma Program · Washington University School of Medicine in St. Louis
Brad Kahl is Professor of Medicine, Division of Oncology; Director, Lymphoma Program at Washington University School of Medicine in St. Louis. OpenAlex indexes 906 publications with 28,153 citations (h-index 74); ClinicalTrials.gov lists 18 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Brad Kahl, MD, is Professor of Medicine, Division of Oncology at Washington University School of Medicine in St. Louis. The public record shows 906 publications with 28,153 citations (h-index 74), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 26 companies.
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Lymphoma Diagnosis and Treatment
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 26 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 48 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 302.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Sponsor: Washington University School of Medicine
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Sponsor: National Cancer Institute (NCI)
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 14 Oct 2026
26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- F. Hoffmann-La Roche AGProgram year20254 payments
- Incyte CorporationProgram year202510 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
45.4%Human Immunoglobulin G44.9%Immune globulin100%Part B, office-administered≥14 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.5%Valacyclovir100%Part D<11 patientsMetabolism & gastrointestinal
16.8%Serotonin-3 Receptor Antagonist14.1%Palonosetron hcl93%Ondansetron Hcl7%Part D + Part B≥23 patientsCorticosteroid1.6%Prednisone100%Part D≥23 patients+ 1 more class in this area
Sensory organs
15.3%Corticosteroid15.3%Dexamethasone sodium phosphate100%Part B, office-administered≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
208 congress contributions (2004–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Outcomes of patients treated for monomorphic B-cell post-transplant lymphoproliferative disorder: A single-center experience.
ASCO Annual Meeting
ASCO2025Co-author - Social genomic mechanisms of health disparities among adolescent/young adult survivors of Hodgkin and non-Hodgkin lymphoma: ECOG-ACRIN EAQ211.
ASCO Annual Meeting
ASCO2025Co-author - Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaArticle1,902 citations2015
- 02Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaArticle1,695 citations2013
- 03
- 04PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaArticle1,062 citations2014
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/brad-kahl-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- X / Twitter
x.com/power4patients/status/1851655959598285117
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- Board Certified in Hematology
American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- Member
NCI Lymphoma Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →siteman.wustl.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ramaswamy Govindan, MD
Washington University School of Medicine in St. Louis
Marin Kollef, MD
Washington University School of Medicine in St. Louis
Mark Huffman, MD
Washington University School of Medicine in St. Louis
Ralph Damiano, MD
Washington University School of Medicine in St. Louis
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center